Orthofix’s Blackstone Medical hires new president to save flagging performance
This article was originally published in Clinica
Brad Mason has been named as the president of Blackstone Medical (Springfield, Massachusetts), the spine implant and biologic subsidiary of Orthofix International. His appointment will not affect his current role as Orthofix’s group president for North America, which will continue. Mr Mason will step into the role formerly held by Oliver Burckhardt, who is leaving the company to pursue other opportunities. Alan Milinazzo, Orthofix CEO said that Blackstone had not performed well during the first half of 2008 and that Mr Mason’s “proven leadership skills” and “extensive product development and distribution experience” were expected to strengthen its capabilities and lift performance.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.